7. CRISPR Therapeutics AG (NASDAQ:CRSP)
Short Float: 30.48%
Market Cap: $5.23 Billion
Stock Upside Potential: 38.03%
CRISPR Therapeutics AG (NASDAQ: CRSP) ranks No. 7 with a short float of 30.48%, a market capitalization of around $5.23 billion, and upside potential of 38.03%. The company develops transformative gene-based medicines using CRISPR/Cas9 gene-editing technology and remains one of the most important names in the gene editing stocks and biotech innovation space.
On May 27, Citizens reiterated a Market Perform rating and a $60 price target on CRISPR Therapeutics. The firm’s stance came as the company maintained a positive outlook on in vivo editing for cardiovascular disease. Clinical data presented at the European Atherosclerosis Society Congress continued to draw attention because gene-editing approaches may offer sustained lipid-lowering effects, a major potential breakthrough in cardiovascular medicine.
CRISPR Therapeutics is advancing a diversified portfolio of in vivo gene-editing programs using its proprietary liver-directed LNP delivery platform. CTX310, which targets ANGPTL3, is progressing in a Phase 1b clinical trial for severe hypertriglyceridemia and refractory hypercholesterolemia. The company is also working on CTX460 for alpha-1 antitrypsin deficiency and CTX340, which targets angiotensinogen for refractory hypertension. With 32 hedge fund holders, CRSP remains a heavily shorted biotech stock that still commands serious attention from institutional investors. For those searching for CRISPR stocks, gene-editing stocks, biotech stocks to buy now, and small-cap healthcare stocks with upside, CRSP continues to offer one of the more science-heavy setups on this list.
Click next to see the following stock...
